4.6 Article

New InhA Inhibitors Based on Expanded Triclosan and Di-Triclosan Analogues to Develop a New Treatment for Tuberculosis

Journal

PHARMACEUTICALS
Volume 14, Issue 4, Pages -

Publisher

MDPI
DOI: 10.3390/ph14040361

Keywords

tuberculosis; structure-based drug-design; molecular modelling; InhA; triazole; triclosan; isoniazid; Mycobacterium tuberculosis; Mycobacterium bovis BCG

Funding

  1. BBSRC
  2. MRC [G0801741]
  3. Wellcome Trust
  4. Wellcome Trust Antimicrobials and Antimicrobial Resistance (AAMR) doctoral training programme Birmingham/Nottingham [203974/Z/17/A]
  5. MRC
  6. MRC [G0801741] Funding Source: UKRI
  7. Wellcome Trust [203974/Z/17/A] Funding Source: Wellcome Trust

Ask authors/readers for more resources

The emergence of multidrug-resistant and extensively drug-resistant tuberculosis has highlighted the urgent need for the development of new anti-TB drugs. Through a rational structure-based drug-design approach and in silico molecular modelling, new flexible ligands were designed and synthesized as potential inhibitors against Mycobacterium tuberculosis. These compounds show promising inhibitory effects and offer opportunities for further optimization.
The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) has reinforced the need for the development of new anti-TB drugs. The first line drug isoniazid inhibits InhA. This is a prodrug requiring activation by the enzyme KatG. Mutations in KatG have largely contributed to clinical isoniazid resistance. We aimed to design new 'direct' InhA inhibitors that obviate the need for activation by KatG, circumventing pre-existing resistance. In silico molecular modelling was used as part of a rational structure-based drug-design approach involving inspection of protein crystal structures of InhA:inhibitor complexes, including the broad spectrum antibiotic triclosan (TCS). One crystal structure exhibited the unusual presence of two triclosan molecules within the Mycobacterium tuberculosis InhA binding site. This became the basis of a strategy for the synthesis of novel inhibitors. A series of new, flexible ligands were designed and synthesised, expanding on the triclosan structure. Low Minimum Inhibitory Concentrations (MICs) were obtained for benzylphenyl compounds (12, 43 and 44) and di-triclosan derivative (39), against Mycobacterium bovis BCG although these may also be inhibiting other enzymes. The ether linked di-triclosan derivative (38) displayed excellent in vitro isolated enzyme inhibition results comparable with triclosan, but at a higher MIC (125 mu g mL(-1)). These compounds offer good opportunities as leads for further optimisation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available